Items Tagged ‘xalkori’

June 5, 2018

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

By

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine […]

View full entry

Tags: crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, MET exon 14 alterations, News, non-small cell lung cancer, nsclc, treatment, xalkori


April 24, 2018

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer

By

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About ALK + NSCLC Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of […]

View full entry

Tags: Alcensa, Alecensa, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, non-small cell lung cancer, xalkori


November 13, 2017

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer

By

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December 2015, Alcensa received accelerated approval for treatment of patients with ALK-positive metastatic NSCLC whose disease progressed on or who were intolerant […]

View full entry

Tags: Alcensa, alectinib, alk, anaplastic lymphoma kinase, crizotinib, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, positive metastatic, Precision Cancer Medicine, xalkori


September 21, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine